Just Published: "Thailand Pharmaceuticals & Healthcare Report Q1 2016"

Thailand's medical system will see a transformation. This comes as there is a growing divergence between the three healthcare schemes in the country in terms of cost as well as healthcare outcomes. In addition, the economy has taken a much stronger precedence under the new military government which will curtail additional funding towards Thailand's healthcare programmes despite the schemes' growing financial constraints. This change could have negative ramifications for drugmakers and healthcare providers - especially should the shift be towards a central agency that negotiates prices for all three programmes.

Headline Expenditure Projections

Pharmaceuticals: THB145.5bn (USD4.5bn) in 2014 to THB152.9bn (USD4.6bn) in 2015; +5.1% in local currency terms and +2.7% in US dollar terms.
Healthcare: THB581.7bn (USD17.9bn) in 2014 to THB621.3bn (USD18.6bn) in 2015: +6.8% in local currency and +4.3% in US dollar terms.

Full Report Details at
- http://www.fastmr.com/prod/1070819_thailand_pharmaceuticals.aspx?afid=301

Risk/Reward Index

In Q415, Thailand remains ranked roughly in the middle of the Pharmaceutical RRI table that assesses the attractiveness of the 19 countries in the Asia Pacific region. This is because while Thailand remains relatively attractive to pharmaceutical investors with its growing pharmaceutical sector, its overall score is dragged down by the risks, including low levels of patent protection that is imposed on drugmakers. As such it scores 16.3 out of a total of 35 on its risk score, significantly below the regional average of 19.5.

Key Trends & Developments

In May 2015, Thailand's Prime Minister Prayut Chain-cha instructed the ministries in charge of public health and commerce to set standard median prices for medical care at private hospitals. Critically, authorities are to ensure that the difference in prices between the private healthcare providers and public hospitals do not remain too large.

The Thailand Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Thailand Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Thailand pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Thailand, to test other views - a key input for successful budgeting and strategic business planning in the Thai pharmaceutical and healthcare market.
* Target business opportunities and risks in the Thai pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Thailand.
*

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Kenya Pharmaceuticals & Healthcare Report Q1 2016
- Pakistan Pharmaceuticals & Healthcare Report Q1 2016
- Argentina Pharmaceuticals & Healthcare Report Q1 2016
- Croatia Pharmaceuticals & Healthcare Report Q1 2016
- Puerto Rico Pharmaceuticals & Healthcare Report Q1 2016